HK IPO Surge Hunter

What It Solves

For HK IPO and recent-listing screening, the hard part is not spotting labels like oversubscription or first-stock status, but separating signals that map to future upside from marketing noise. This skill frames the problem in one measurable way: whether the current price still has at least 50% upside from the issue price. It covers two cases: un-doubled IPOs, where the focus is on the probability of reaching 2x the issue price, and already-doubled names, where the focus shifts to whether another 50% move is still reasonable. The output is not a raw watchlist, but a ranked score and attribution report under a single perspective.

How It Works

The skill is organized around three workflows: V7 IPO scoring, second-surge evaluation, and unified screening.

• Data collection: It pulls prospectus details, placement results, sector attributes, VC/PE support, cornerstone investors, 18A status, R&D, and revenue growth signals; issue price and real-time price are cross-checked against multiple sources to reduce conclusion drift from bad inputs.
• Scoring: Undoubled names use the V7 model, built from 17 scoring factors and 5 interaction factors. Already-doubled names switch to the second-surge model, which evaluates sector momentum, earnings realization, institutional coverage, catalyst pipeline, and valuation headroom.
• Reporting: It can generate single-name scores, multi-name comparisons, pre-listing estimates, post-placement reviews, and post-listing attribution. The report logic also constrains headline selection, preferring high-signal factors instead of packaging weak indicators as the main selling point.

Boundaries

This is best treated as a research and screening framework, not a trading instruction. The sample is based on 2025-2026 HK IPOs, and some factors are sensitive to the AI-led market cycle; in weaker or rotating sectors, weights and conclusions may need review. Score quality also depends on external data, especially issue price, first-day move, and real-time quotes. Before acting on any result, treat the report as factor decomposition and risk flagging, not as a final buy, sell, or add-position decision.